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There are a number of tests available for assessment of anterior pituitary hormone function. Recent concern has centred on the use of provocative tests for growth hormone release and in particular the glucagon and insulin induced hypoglycaemia or insulin tolerance test (ITT). These tests have been associated with cerebral oedema and death of at least two children and, as a result, questions have been raised as to the current management and investigation of children with potential abnormalities of growth hormone secretion. I This review describes the background and theory behind the tests as well as an appraisal of some of the more common methods of assessing growth hormone release. It does not provide detailed information on the construction of 12 or 24 hour profiles of growth hormone secretion, as it is not felt that these are applicable to routine clinical investigation.
Central to the use of any test are its performance characteristics in terms of efficiency, sensitivity, and specificity. Attention must also be paid to the method used to measure growth hormone in the serum. This review attempts to assess the importance of these issues. Epidemiological studies would suggest that idiopathic isolated growth hormone deficiency occurs more frequently than multiple pituitary hormone deficiency. It is not always possible, however, for the clinician to be sure that there is no other associated anterior pituitary hormone deficiency in addition to growth hormone insufficiency. Further, the loss of anterior pituitary hormones in multiple pituitary hormone deficiency most often starts with growth hormone. This pattern of loss may be of relevance in ascertaining the correct underlying diagnosis and whether other investigations such as a computed tomography or magnetic resonance imaging are required. Thyroxine and cortisol are important in the regulation of the growth hormone gene so that knowledge of thyroxine and cortisol status is essential before embarking on growth hormone testing. Thyroxine can be easily measured on a single blood specimen but the integrity of the pituitary-adrenal axis is more difficult to assess with a single random morning blood sample because of the pulsatility of cortisol.4 In practice most clinicians before embarking on growth hormone assessment in a slowly growing child would attempt to confirm adequate thyroid and cortisol concentrations as well as measuring a full blood count and assessing renal function. Antigliadin antibodies might be measured and a karyotype examined particularly in girls. Any doubt about the cortisol status makes a more comprehensive assessment in the specialised endocrine centre absolutely mandatory.
Growth hormone release is under the control of the two hypothalamic peptides, growth hormone releasing hormone (GHRH) and somatostatin. Recent work has suggested that endogenous GHRH is extremely important in determining the magnitude of the growth hormone secretory burst, whereas somatostatin is important in determining the timing of that event. 5 The stimuli used to provoke growth hormone secretion probably act through either or both of these peptides. In man there is no clear evidence to determine upon which of the pathways the various stimuli act. Therefore, it is difficult to compare the results of individual tests, although it is generally accepted that a cut off growth hormone peak response of 7 5-10 pg/l (15) (16) (17) (18) (19) (20) Few comparative studies have used growth rate as part of the definition for interpreting results. What has usually happened is that the ITT and other tests have been compared. Not surprisingly the ITT has scored extremely well because, being the standard, it is allocated a value of 100%!9 Table 1 provides an analysis of ITT performance against growth rate10 and A number of reasons have been proposed to explain the discordance between the results obtained from growth hormone testing compared with prolonged observation of growth velocity in children. First, a raised growth hormone concentration at time 0 during the test leads to difficulty in interpretation. Tests are designed to evaluate the secretory pathway, particularly the readily releasable pool of growth hormone. If there has recently been a pulse of growth hormone and the pool is low, the subsequent response will be attenuated.'3 Ideally, before any test, there should be a run in period where samples are obtained for at least 30 and preferably 60 minutes before the study in order that the response can be interpreted in the light of possible previous secretory episodes.
Second, children's growth varies with the seasons and there is evidence to suggest cycles of periodicity greater than one year.16 Growth hormone secretion is related to growth rate17-19 and it is possible that some of the discordance could be explained by the performance of the test during a period of relatively faster growth when growth hormone secretion was greater whereas annualised growth rate might indicate a different picture of overall growth failure. This highlights the difficulty of comparing one year of growth data with a one day stimulation test. Further, the relation between growth rate and growth hormone secretion is a continuum so any cut off value chosen to separate normality from abnormality is a compromise balancing sensitivity and specificity.
A third source of discordance is that a particular stimulus might release pituitary hormones when the problem is in the hypothalamus. It is important therefore to use stimuli which seem to act predominantly on the hypothalamus (for example, ITT, clonidine) rather than the pituitary gland (for example, GHRH).
Finally, the reproducibility of any test needs to be considered. A number of studies have demonstrated that the reproducibility of the physiological and pharmacological methods of assessing growth hormone secretion in an individual is poor.20-22 Interindividual and intraindividual variation is considerable and makes interpretation difficult (table 3) . 
Pubertal delay
In certain situations, it may be difficult to ascertain whether a child who is growing slowly with constitutional delay of growth and puberty is going to have an adequate pubertal growth spurt. In such a situation, it may be valuable to perform a growth hormone provocation test following 'priming' with exogenous sex steroid before the start of the investigation. The aim of this investigation is to ascertain whether there is going to be sufficient growth hormone available during the puberty growth spurt. Priming has usually been performed in males by giving a single intramuscular injection of testosterone (100 mg) three days before the investigation or in females by giving ethinyloestradiol or stilboestrol (1 mg twice a day for two days). The latter can actually be used quite satisfactorily in both sexes.8 25 As a first principle all these tests require good venous access. A nurse and a doctor should be present throughout the procedure and facilities for resuscitation need to be available. All of the tests were standardised in adults after an overnight fast. Fasting from midnight is the ideal but young children should be encouraged to have a late night snack and infants should not starve for more than six hours. Drinks of water are allowed.
After insertion of an intravenous cannula a period of acclimatisation should be allowed. Whenever possible, the test should be started by drawing a sample of blood 15-30 minutes before the application of the stimulus. This sample together with the 0 minute sample gives an idea of the growth hormone secretory status after the cannula is inserted before the time that the study is carried out. High growth hormone values which are declining during this time period are often associated with a poor response to the stimulus. The growth hormone response may be impaired if hypoglycaemia is inadequate. An adequate hypoglycaemic stimulus is when the blood glucose falls to 2-2 mmolI or less, if the child is symptomatic, or if there is a 50% reduction in the blood glucose concentration.34 Blood samples need to be drawn at 30 minute intervals for two hours.
Lunch should be provided for the child at the end of the test and the child should not be sent home until an adequate meal has been taken and observed for at least 90 minutes after the meal to make certain that there is no vomiting. The intravenous cannula should be left in situ until lunch has been assimilated. If there is any doubt about the child's wellbeing overnight observation is recommended. Care needs to be exercised in interpreting the cortisol response to the glucagon test. Peak ACTH concentrations are significantly less during glucagon than during the ITT and are also delayed. 35 Higher and more consistent cortisol levels are obtained after intramuscular administration than after the subcutaneous route.36 37 Problems with hypoglycaemia may arise particularly in young children if glycogen stores are depleted by an overnight fast before the administration of glucagon and as recommended above for the ITT, lunch must be seen to be absorbed after the test before the intravenous cannula is removed. The test is contraindicated when cortisol deficiency is suspected as glycogen stores are likely to be low. Growth hormone assays There has been a recent increase in the number of growth hormone assays available for the measurement of serum growth hormone concentration. These methods range from the traditional polyclonal methodology using radioimmunoassay to sophisticated monoclonal radioimmunometric assays. Sensitivity has been greatly improved by the use of enzyme linked or chemiluminescent systems. The variety of assays introduces further problems in the interpretation of growth hormone responses.
Assays employ different reaction matrices and are almost certain to use antisera with differing epitope specificity so that universal cut off values, for example 7 5 ,ug/l (15 mU/l), may not be appropriate using different assay systems. Care must be exercised in interpreting results from different laboratories. The clinician needs to be aware of the method in current use, the precision profile of that assay, and how the laboratory performs within the UK external quality assurance scheme. Table  1 shows the results of using the Hybritech system for measuring growth hormone.
Conclusions
Growth hormone provocation tests should be used only after careful clinical assessment has confirmed inadequate growth velocity, other potential causes of growth failure have been excluded, and that there is a real possibility of hypothalamic or pituitary hormone deficiency. These tests should be performed only in centres where there is experience in performing and interpreting them. The clonidine test is the most useful for paediatric practice. ITT and glucagon tests should only be used in specialist centres.
There remains the question of whether any growth hormone test should be performed in the assessment of the slowly growing child. Although idiopathic isolated growth hormone insufficiency is one of the commonest endocrine causes of poor growth the clinical features are poor indicators of the diagnosis or whether there is an isolated or multiple pituitary deficiency. In the neonatal period and after cranial irradiation there are clearer indications for testing.
The authors consider that growth hormone measurements remain a valid investigation in order to provide biochemical support for subsequent growth hormone treatment. Despite the statistical constraints of the tests the likelihood that a slowly growing child is growth hormone insufficient is increased twofold in the presence of a positive test but only decreased by half in the presence of a negative one. Improving the probability of the presence of a growth hormone secretory disorder is particularly important if general practitioners are to be asked to prescribe and, therefore, to take some shared responsibility for the prescription. Also, detailed evaluation would seem to be a prerequisite for outcome audit and research purposes. Advances in cellular and molecular biology will gradually clarify the diagnosis of idiopathic isolated growth hormone insufficiency but these techniques will only be as good as the defined phenotype.
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